FDA Adverse Event Injury Summary report: N

WATCHMAN LAA CLOSURE DEVICE & DELIVERY SYSTEM

MDR report key: 11922782 · Received June 2, 2021

Report

Report Number
2134265-2021-06755
Event Type
Injury
Date Received
June 2, 2021
Date of Event
May 11, 2021
Report Date
January 6, 2023
Manufacturer
BOSTON SCIENTIFIC CORPORATION
Product Code
NGV
UDI-DI
08714729838234
PMA / PMN Number
P130013
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
IL, US
Reporter Occupation
PHYSICIAN
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

A1: PATIENT ID - (B)(6).

Additional Manufacturer Narrative · 0

A1: PATIENT ID: (B)(6).

Additional Manufacturer Narrative · 0

A1: PATIENT ID - (B)(6). B5: DESCRIBE EVENT OR PROBLEM - UPDATED. H6: PATIENT CODES- UPDATED. H6: IMPACT CODES- UPDATED.

Additional Manufacturer Narrative · 0

A1: PATIENT ID - (B)(6).

Additional Manufacturer Narrative · 0

B6: RELEVANT TESTS/LABORATORY DATA- UPDATED. B7: OTHER RELEVANT HISTORY - UPDATED.

Description of Event or Problem · 0

ASAP TOO STUDY. IT WAS REPORTED THAT A CEREBRAL VASCULAR ACCIDENT (CVA) AND THROMBOSIS OCCURRED. THE PATIENT WAS ON ASPIRIN PRIOR TO THE INDEX PROCEDURE. ON (B)(6) 2020, A LEFT ATRIAL APPENDAGE (LAA) CLOSURE PROCEDURE WAS PERFORMED AND A 24MM WATCHMAN LAA CLOSURE DEVICE WAS IMPLANTED WITH A COMPLETE LAA SEAL AND DEPLOYED DEVICE DIAMETER OF 21MM. AFTER THE IMPLANT, THE PATIENT WAS STARTED ON CLOPIDOGREL. THE POST IMPLANT TRANSESOPHAGEAL ECHOCARDIOGRAM (TEE) REVEALED A COMPLETE LAA SEAL. THE PATIENT WAS DISCHARGED ON (B)(6) 2020. ON (B)(6) 2021, 319 DAYS POST INDEX PROCEDURE, THE PATIENT WAS DIAGNOSED WITH A STROKE. THE PATIENT WAS ON ASPIRIN AND CLOPIDOGREL AT THE TIME OF THE EVENT. THE DURATION OF FOCAL OR GLOBAL NEUROLOGICAL DEFICIT WAS GREATER THAN 24 HOURS IN THE OF IMAGING-DOCUMENTED NEW HEMORRHAGE OR INFARCT. ON (B)(6) 2021, THE NATIONAL INSTITUTES OF HEALTH (NIH) STROKE SCALE WAS 1. THE BASELINE NIH STROKE SCALE THAT WAS PERFORMED ON (B)(6) 2020 WAS 0. ON (B)(6) 2021, 321 DAYS POST INDEX PROCEDURE, THE PATIENT PRESENTED TO THE ENROLLING SITE FOR A 12 MONTH FOLLOW UP, WHICH REVEALED THROMBUS ON THE DEVICE AND WORSENED LEAK OF 4MM AROUND THE WATCHMAN DEVICE. IT WAS FURTHER REPORTED THAT THE PATIENT PRESENTED TO THE EMERGENCY DEPARTMENT ON (B)(6) 2021 WITH APHASIA SUSPICIOUS TO STROKE AND THE PATIENT WAS THUS ADMITTED BY NEUROLOGY. ON THE SAME DAY, MAGNETIC RESONANCE IMAGING (MRI) REVEALED PATCHY FOCI OF DIFFUSION RESTRICTION AND CORRESPONDING T2 FLAIR HYPERINTENSITY SEEN IN THE LEFT FRONTAL TEMPORAL PARENCHYMA WITH ADDITIONAL TINY RECENT INFARCTS IN THE RIGHT FRONTAL LOBE AND RIGHT CEREBELLUM IN ADDITION TO SMALL VESSEL DISEASE, OLD INFARCTS, AND VOLUME LOSS. THE THROMBUS WAS ON THE ATRIAL FACING SURFACE OF THE CLOSURE DEVICE AND WAS 10 X 6MM IN SIZE. THE THROMBUS WAS IDENTIFIED VIA TEE. THE PATIENT WAS STARTED ON PLAVIX AND ELIQUIS. THE PATIENT WAS STABLE AND DISCHARGED HOME ON (B)(6) 2021.

Description of Event or Problem · 0

ASAP TOO STUDY. IT WAS REPORTED THAT A CEREBRAL VASCULAR ACCIDENT (CVA) AND THROMBOSIS OCCURRED. THE PATIENT WAS ON ASPIRIN PRIOR TO THE INDEX PROCEDURE. ON (B)(6) 2020, A LEFT ATRIAL APPENDAGE (LAA) CLOSURE PROCEDURE WAS PERFORMED AND A 24MM WATCHMAN LAA CLOSURE DEVICE WAS IMPLANTED WITH A COMPLETE LAA SEAL AND DEPLOYED DEVICE DIAMETER OF 21MM. AFTER THE IMPLANT, THE PATIENT WAS STARTED ON CLOPIDOGREL. THE POST IMPLANT TRANSESOPHAGEAL ECHOCARDIOGRAM (TEE) REVEALED A COMPLETE LAA SEAL. THE PATIENT WAS DISCHARGED ON (B)(6) 2020. ON (B)(6) 2021, 319 DAYS POST INDEX PROCEDURE, THE PATIENT WAS DIAGNOSED WITH A STROKE. THE PATIENT WAS ON ASPIRIN AND CLOPIDOGREL AT THE TIME OF THE EVENT. THE DURATION OF FOCAL OR GLOBAL NEUROLOGICAL DEFICIT WAS GREATER THAN 24 HOURS IN THE OF IMAGING-DOCUMENTED NEW HEMORRHAGE OR INFARCT. ON (B)(6) 2021, THE NATIONAL INSTITUTES OF HEALTH (NIH) STROKE SCALE WAS 1. THE BASELINE NIH STROKE SCALE THAT WAS PERFORMED ON (B)(6) 2020 WAS 0. ON (B)(6) 2021, 321 DAYS POST INDEX PROCEDURE, THE PATIENT PRESENTED TO THE ENROLLING SITE FOR A 12 MONTH FOLLOW UP, WHICH REVEALED THROMBUS ON THE DEVICE AND WORSENED LEAK OF 4MM AROUND THE WATCHMAN DEVICE. IT WAS FURTHER REPORTED THAT THE PATIENT PRESENTED TO THE EMERGENCY DEPARTMENT ON (B)(6) 2021 WITH APHASIA SUSPICIOUS TO STROKE AND THE PATIENT WAS THUS ADMITTED BY NEUROLOGY. ON THE SAME DAY, MAGNETIC RESONANCE IMAGING (MRI) REVEALED PATCHY FOCI OF DIFFUSION RESTRICTION AND CORRESPONDING T2 FLAIR HYPERINTENSITY SEEN IN THE LEFT FRONTAL TEMPORAL PARENCHYMA WITH ADDITIONAL TINY RECENT INFARCTS IN THE RIGHT FRONTAL LOBE AND RIGHT CEREBELLUM IN ADDITION TO SMALL VESSEL DISEASE, OLD INFARCTS, AND VOLUME LOSS. THE THROMBUS WAS ON THE ATRIAL FACING SURFACE OF THE CLOSURE DEVICE AND WAS 10 X 6MM IN SIZE. THE THROMBUS WAS IDENTIFIED VIA TEE. THE PATIENT WAS STARTED ON PLAVIX AND ELIQUIS. THE PATIENT WAS STABLE AND DISCHARGED HOME ON (B)(6) 2021.

Description of Event or Problem · 0

ASAP TOO STUDY. IT WAS REPORTED THAT A CEREBRAL VASCULAR ACCIDENT (CVA) AND THROMBOSIS OCCURRED. THE PATIENT WAS ON ASPIRIN PRIOR TO THE INDEX PROCEDURE. ON (B)(6) 2020, A LEFT ATRIAL APPENDAGE (LAA) CLOSURE PROCEDURE WAS PERFORMED AND A 24MM WATCHMAN LAA CLOSURE DEVICE WAS IMPLANTED WITH A COMPLETE LAA SEAL AND DEPLOYED DEVICE DIAMETER OF 21MM. AFTER THE IMPLANT, THE PATIENT WAS STARTED ON CLOPIDOGREL. THE POST IMPLANT TRANSESOPHAGEAL ECHOCARDIOGRAM (TEE) REVEALED A COMPLETE LAA SEAL. THE PATIENT WAS DISCHARGED ON (B)(6) 2020. ON (B)(6) 2021, 319 DAYS POST INDEX PROCEDURE, THE PATIENT WAS DIAGNOSED WITH A STROKE. THE PATIENT WAS ON ASPIRIN AND CLOPIDOGREL AT THE TIME OF THE EVENT. THE DURATION OF FOCAL OR GLOBAL NEUROLOGICAL DEFICIT WAS GREATER THAN 24 HOURS IN THE OF IMAGING-DOCUMENTED NEW HEMORRHAGE OR INFARCT. ON (B)(6) 2021, THE NATIONAL INSTITUTES OF HEALTH (NIH) STROKE SCALE WAS 1. THE BASELINE NIH STROKE SCALE THAT WAS PERFORMED ON (B)(6) 2020 WAS 0. ON (B)(6) 2021, 321 DAYS POST INDEX PROCEDURE, THE PATIENT PRESENTED TO THE ENROLLING SITE FOR A 12 MONTH FOLLOW UP, WHICH REVEALED THROMBUS ON THE DEVICE AND WORSENED LEAK OF 4MM AROUND THE WATCHMAN DEVICE. IT WAS FURTHER REPORTED THAT THE PATIENT PRESENTED TO THE EMERGENCY DEPARTMENT ON (B)(6) 2021 WITH APHASIA SUSPICIOUS TO STROKE AND THE PATIENT WAS THUS ADMITTED BY NEUROLOGY. ON THE SAME DAY, MAGNETIC RESONANCE IMAGING (MRI) REVEALED PATCHY FOCI OF DIFFUSION RESTRICTION AND CORRESPONDING T2 FLAIR HYPERINTENSITY SEEN IN THE LEFT FRONTAL TEMPORAL PARENCHYMA WITH ADDITIONAL TINY RECENT INFARCTS IN THE RIGHT FRONTAL LOBE AND RIGHT CEREBELLUM IN ADDITION TO SMALL VESSEL DISEASE, OLD INFARCTS, AND VOLUME LOSS. THE THROMBUS WAS ON THE ATRIAL FACING SURFACE OF THE CLOSURE DEVICE AND WAS 10 X 6MM IN SIZE. THE THROMBUS WAS IDENTIFIED VIA TEE. THE PATIENT WAS STARTED ON PLAVIX AND ELIQUIS. THE PATIENT WAS STABLE AND DISCHARGED HOME ON (B)(6) 2021. IT WAS FURTHER REPORTED THAT COMPUTED TOMOGRAPHY (CT) OF THE HEAD WAS PERFORMED WHICH REVEALED FINDINGS OF CHRONIC SMALL VESSEL ISCHEMIC CHANGES AND NO ACUTE INTRACRANIAL ABNORMALITY. ON THE SAME DAY, CT OF THE HEAD AND NECK WAS ALSO PERFORMED WHICH REVEALED NO EVIDENCE OF CAROTID STENOSIS, BOTH VERTEBRAL ARTERIES ARE WIDELY PATENT TO THE LEVEL OF BASILAR, NO EVIDENCE OF FOCAL FILING DEFECT OR ABRUPT CUT OFF TO SUGGEST ACUTE CENTRAL CIRCLE OF WILLIS LARGE VESSEL OCCLUSION AND 7 MM INDETERMINATE NODULE LEFT APEX INCIDENTALLY NOTED. A 7 MM INDETERMINATE NODULE LEFT LUNG APEX WAS ALSO NOTED.

Description of Event or Problem · 0

ASAP TOO STUDY. IT WAS REPORTED THAT A CEREBRAL VASCULAR ACCIDENT (CVA) AND THROMBOSIS OCCURRED. THE PATIENT WAS ON ASPIRIN PRIOR TO THE INDEX PROCEDURE. ON (B)(6) 2020, A LEFT ATRIAL APPENDAGE (LAA) CLOSURE PROCEDURE WAS PERFORMED AND A 24MM WATCHMAN LAA CLOSURE DEVICE WAS IMPLANTED WITH A COMPLETE LAA SEAL AND DEPLOYED DEVICE DIAMETER OF 21MM. AFTER THE IMPLANT, THE PATIENT WAS STARTED ON CLOPIDOGREL. THE POST IMPLANT TRANSESOPHAGEAL ECHOCARDIOGRAM (TEE) REVEALED A COMPLETE LAA SEAL. THE PATIENT WAS DISCHARGED ON (B)(6) 2020. ON (B)(6) 2021, 319 DAYS POST INDEX PROCEDURE, THE PATIENT WAS DIAGNOSED WITH A STROKE. THE PATIENT WAS ON ASPIRIN AND CLOPIDOGREL AT THE TIME OF THE EVENT. THE DURATION OF FOCAL OR GLOBAL NEUROLOGICAL DEFICIT WAS GREATER THAN 24 HOURS IN THE OF IMAGING-DOCUMENTED NEW HEMORRHAGE OR INFARCT. ON (B)(6) 2021, THE NATIONAL INSTITUTES OF HEALTH (NIH) STROKE SCALE WAS 1. THE BASELINE NIH STROKE SCALE THAT WAS PERFORMED ON (B)(6) 2020 WAS 0. ON (B)(6) 2021, 321 DAYS POST INDEX PROCEDURE, THE PATIENT PRESENTED TO THE ENROLLING SITE FOR A 12 MONTH FOLLOW UP, WHICH REVEALED THROMBUS ON THE DEVICE AND WORSENED LEAK OF 4MM AROUND THE WATCHMAN DEVICE. IT WAS FURTHER REPORTED THAT THE PATIENT PRESENTED TO THE EMERGENCY DEPARTMENT ON (B)(6) 2021 WITH APHASIA SUSPICIOUS TO STROKE AND THE PATIENT WAS THUS ADMITTED BY NEUROLOGY. ON THE SAME DAY, MAGNETIC RESONANCE IMAGING (MRI) REVEALED PATCHY FOCI OF DIFFUSION RESTRICTION AND CORRESPONDING T2 FLAIR HYPERINTENSITY SEEN IN THE LEFT FRONTAL TEMPORAL PARENCHYMA WITH ADDITIONAL TINY RECENT INFARCTS IN THE RIGHT FRONTAL LOBE AND RIGHT CEREBELLUM IN ADDITION TO SMALL VESSEL DISEASE, OLD INFARCTS, AND VOLUME LOSS. THE THROMBUS WAS ON THE ATRIAL FACING SURFACE OF THE CLOSURE DEVICE AND WAS 10 X 6MM IN SIZE. THE THROMBUS WAS IDENTIFIED VIA TEE. THE PATIENT WAS STARTED ON PLAVIX AND ELIQUIS. THE PATIENT WAS STABLE AND DISCHARGED HOME ON (B)(6) 2021. IT WAS FURTHER REPORTED THAT COMPUTED TOMOGRAPHY (CT) OF THE HEAD WAS PERFORMED WHICH REVEALED FINDINGS OF CHRONIC SMALL VESSEL ISCHEMIC CHANGES AND NO ACUTE INTRACRANIAL ABNORMALITY. ON THE SAME DAY, CT OF THE HEAD AND NECK WAS ALSO PERFORMED WHICH REVEALED NO EVIDENCE OF CAROTID STENOSIS, BOTH VERTEBRAL ARTERIES ARE WIDELY PATENT TO THE LEVEL OF BASILAR, NO EVIDENCE OF FOCAL FILING DEFECT OR ABRUPT CUT OFF TO SUGGEST ACUTE CENTRAL CIRCLE OF WILLIS LARGE VESSEL OCCLUSION AND 7 MM INDETERMINATE NODULE LEFT APEX INCIDENTALLY NOTED. A 7 MM INDETERMINATE NODULE LEFT LUNG APEX WAS ALSO NOTED. IT WAS FURTHER REPORTED THAT THOUGH THE SITE DID NOT DOWNGRADE THE CAUSALITY OF THE THROMBUS, THE THROMBUS WAS CONFIRMED VIA IMAGING TO NOT BE ON THE ATRIAL FACING SIDE OF THE CLOSURE DEVICE. THUS, THE CLOSURE DEVICE WAS PERFORMING AS INTENDED.

Description of Event or Problem · 0

ASAP TOO STUDY. IT WAS REPORTED THAT A CEREBRAL VASCULAR ACCIDENT (CVA) AND THROMBOSIS OCCURRED. THE PATIENT WAS ON ASPIRIN PRIOR TO THE INDEX PROCEDURE. ON (B)(6) 2020, A LEFT ATRIAL APPENDAGE (LAA) CLOSURE PROCEDURE WAS PERFORMED AND A 24MM WATCHMAN LAA CLOSURE DEVICE WAS IMPLANTED WITH A COMPLETE LAA SEAL AND DEPLOYED DEVICE DIAMETER OF 21MM. AFTER THE IMPLANT, THE PATIENT WAS STARTED ON CLOPIDOGREL. THE POST IMPLANT TRANSESOPHAGEAL ECHOCARDIOGRAM (TEE) REVEALED A COMPLETE LAA SEAL. THE PATIENT WAS DISCHARGED ON (B)(6) 2020. ON (B)(6) 2021, 319 DAYS POST INDEX PROCEDURE, THE PATIENT WAS DIAGNOSED WITH A STROKE. THE PATIENT WAS ON ASPIRIN AND CLOPIDOGREL AT THE TIME OF THE EVENT. THE DURATION OF FOCAL OR GLOBAL NEUROLOGICAL DEFICIT WAS GREATER THAN 24 HOURS IN THE OF IMAGING-DOCUMENTED NEW HEMORRHAGE OR INFARCT. ON (B)(6) 2021, THE NATIONAL INSTITUTES OF HEALTH (NIH) STROKE SCALE WAS 1. THE BASELINE NIH STROKE SCALE THAT WAS PERFORMED ON (B)(6) 2020 WAS 0. ON (B)(6) 2021, 321 DAYS POST INDEX PROCEDURE, THE PATIENT PRESENTED TO THE ENROLLING SITE FOR A 12 MONTH FOLLOW UP, WHICH REVEALED THROMBUS ON THE DEVICE AND WORSENED LEAK OF 4MM AROUND THE WATCHMAN DEVICE. IT WAS FURTHER REPORTED THAT THE PATIENT PRESENTED TO THE EMERGENCY DEPARTMENT ON (B)(6) 2021 WITH APHASIA SUSPICIOUS TO STROKE AND THE PATIENT WAS THUS ADMITTED BY NEUROLOGY. ON THE SAME DAY, MAGNETIC RESONANCE IMAGING (MRI) REVEALED PATCHY FOCI OF DIFFUSION RESTRICTION AND CORRESPONDING T2 FLAIR HYPERINTENSITY SEEN IN THE LEFT FRONTAL TEMPORAL PARENCHYMA WITH ADDITIONAL TINY RECENT INFARCTS IN THE RIGHT FRONTAL LOBE AND RIGHT CEREBELLUM IN ADDITION TO SMALL VESSEL DISEASE, OLD INFARCTS, AND VOLUME LOSS. THE THROMBUS WAS ON THE ATRIAL FACING SURFACE OF THE CLOSURE DEVICE AND WAS 10 X 6MM IN SIZE. THE THROMBUS WAS IDENTIFIED VIA TEE. THE PATIENT WAS STARTED ON PLAVIX AND ELIQUIS. THE PATIENT WAS STABLE AND DISCHARGED HOME ON (B)(6) 2021. IT WAS FURTHER REPORTED THAT COMPUTED TOMOGRAPHY (CT) OF THE HEAD WAS PERFORMED WHICH REVEALED FINDINGS OF CHRONIC SMALL VESSEL ISCHEMIC CHANGES AND NO ACUTE INTRACRANIAL ABNORMALITY. ON THE SAME DAY, CT OF THE HEAD AND NECK WAS ALSO PERFORMED WHICH REVEALED NO EVIDENCE OF CAROTID STENOSIS, BOTH VERTEBRAL ARTERIES ARE WIDELY PATENT TO THE LEVEL OF BASILAR, NO EVIDENCE OF FOCAL FILING DEFECT OR ABRUPT CUT OFF TO SUGGEST ACUTE CENTRAL CIRCLE OF WILLIS LARGE VESSEL OCCLUSION AND 7 MM INDETERMINATE NODULE LEFT APEX INCIDENTALLY NOTED. A 7 MM INDETERMINATE NODULE LEFT LUNG APEX WAS ALSO NOTED. IT WAS FURTHER REPORTED THAT THOUGH THE SITE DID NOT DOWNGRADE THE CAUSALITY OF THE THROMBUS, THE THROMBUS WAS CONFIRMED VIA IMAGING TO NOT BE ON THE ATRIAL FACING SIDE OF THE CLOSURE DEVICE. THUS, THE CLOSURE DEVICE WAS PERFORMING AS INTENDED. IT WAS FURTHER REPORTED THAT THE CAUSALITY OF THE THROMBUS WAS NOW DOWNGRADED BY THE SITE AS THE THROMBUS WAS CONFIRMED VIA IMAGING TO NOT BE ON THE ATRIAL FACING SIDE OF THE CLOSURE DEVICE AND THE CLOSURE DEVICE WAS PERFORMING AS INTENDED.

Description of Event or Problem · 0

ASAP TOO STUDY. IT WAS REPORTED THAT A CEREBRAL VASCULAR ACCIDENT (CVA) AND THROMBOSIS OCCURRED. THE PATIENT WAS ON ASPIRIN PRIOR TO THE INDEX PROCEDURE. ON (B)(6) 2020, A LEFT ATRIAL APPENDAGE (LAA) CLOSURE PROCEDURE WAS PERFORMED AND A 24MM WATCHMAN LAA CLOSURE DEVICE WAS IMPLANTED WITH A COMPLETE LAA SEAL AND DEPLOYED DEVICE DIAMETER OF 21MM. AFTER THE IMPLANT, THE PATIENT WAS STARTED ON CLOPIDOGREL. THE POST IMPLANT TRANSESOPHAGEAL ECHOCARDIOGRAM (TEE) REVEALED A COMPLETE LAA SEAL. THE PATIENT WAS DISCHARGED ON (B)(6) 2020. ON (B)(6) 2021, 319 DAYS POST INDEX PROCEDURE, THE PATIENT WAS DIAGNOSED WITH A STROKE. THE PATIENT WAS ON ASPIRIN AND CLOPIDOGREL AT THE TIME OF THE EVENT. THE DURATION OF FOCAL OR GLOBAL NEUROLOGICAL DEFICIT WAS GREATER THAN 24 HOURS IN THE OF IMAGING-DOCUMENTED NEW HEMORRHAGE OR INFARCT. ON (B)(6) 2021, THE NATIONAL INSTITUTES OF HEALTH (NIH) STROKE SCALE WAS 1. THE BASELINE NIH STROKE SCALE THAT WAS PERFORMED ON (B)(6) 2020 WAS 0. ON (B)(6) 2021, 321 DAYS POST INDEX PROCEDURE, THE PATIENT PRESENTED TO THE ENROLLING SITE FOR A 12 MONTH FOLLOW UP, WHICH REVEALED THROMBUS ON THE DEVICE AND WORSENED LEAK OF 4MM AROUND THE WATCHMAN DEVICE. IT WAS FURTHER REPORTED THAT THE PATIENT PRESENTED TO THE EMERGENCY DEPARTMENT ON (B)(6) 2021 WITH APHASIA SUSPICIOUS TO STROKE AND THE PATIENT WAS THUS ADMITTED BY NEUROLOGY. ON THE SAME DAY, MAGNETIC RESONANCE IMAGING (MRI) REVEALED PATCHY FOCI OF DIFFUSION RESTRICTION AND CORRESPONDING T2 FLAIR HYPERINTENSITY SEEN IN THE LEFT FRONTAL TEMPORAL PARENCHYMA WITH ADDITIONAL TINY RECENT INFARCTS IN THE RIGHT FRONTAL LOBE AND RIGHT CEREBELLUM IN ADDITION TO SMALL VESSEL DISEASE, OLD INFARCTS, AND VOLUME LOSS. THE THROMBUS WAS ON THE ATRIAL FACING SURFACE OF THE CLOSURE DEVICE AND WAS 10 X 6MM IN SIZE. THE THROMBUS WAS IDENTIFIED VIA TEE. THE PATIENT WAS STARTED ON PLAVIX AND ELIQUIS. THE PATIENT WAS STABLE AND DISCHARGED HOME ON (B)(6) 2021.

Additional Manufacturer Narrative · 1

PATIENT ID: (B)(6).

Description of Event or Problem · 1

(B)(6) STUDY. IT WAS REPORTED THAT A CEREBRAL VASCULAR ACCIDENT (CVA) AND THROMBOSIS OCCURRED. THE PATIENT WAS ON ASPIRIN PRIOR TO THE INDEX PROCEDURE. ON (B)(6) 2020, A LEFT ATRIAL APPENDAGE (LAA) CLOSURE PROCEDURE WAS PERFORMED AND A 24MM WATCHMAN LAA CLOSURE DEVICE WAS IMPLANTED WITH A COMPLETE LAA SEAL AND DEPLOYED DEVICE DIAMETER OF 21MM. AFTER THE IMPLANT, THE PATIENT WAS STARTED ON CLOPIDOGREL. THE POST IMPLANT TRANSESOPHAGEAL ECHOCARDIOGRAM (TEE) REVEALED A COMPLETE LAA SEAL. THE PATIENT WAS DISCHARGED ON (B)(6) 2020. ON (B)(6) 2021, 319 DAYS POST INDEX PROCEDURE, THE PATIENT WAS DIAGNOSED WITH A STROKE. THE PATIENT WAS ON ASPIRIN AND CLOPIDOGREL AT THE TIME OF THE EVENT. THE DURATION OF FOCAL OR GLOBAL NEUROLOGICAL DEFICIT WAS GREATER THAN 24 HOURS IN THE OF IMAGING-DOCUMENTED NEW HEMORRHAGE OR INFARCT. ON (B)(6) 2021, THE NATIONAL INSTITUTES OF HEALTH (NIH) STROKE SCALE WAS 1. THE BASELINE NIH STROKE SCALE THAT WAS PERFORMED ON (B)(6) 2020 WAS 0. ON (B)(6) 2021, 321 DAYS POST INDEX PROCEDURE, THE PATIENT PRESENTED TO THE ENROLLING SITE FOR A 12 MONTH FOLLOW UP, WHICH REVEALED THROMBUS ON THE DEVICE AND WORSENED LEAK OF 4MM AROUND THE WATCHMAN DEVICE.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
820921 WATCHMAN LAA CLOSURE DEVICE & DELIVERY SYSTEM SYSTEM, APPENDAGE CLOSURE, LEFT ATRIAL NGV BOSTON SCIENTIFIC CORPORATION 10371 0024778517 08714729838234

Patients

Seq Age Sex Outcome Treatment
1 81 YR Female Required Intervention| O